Proteomics analysis indicates that HBOT treatment can reduce the serum S100A9 levels in patients with ANFH, thereby mitigating its inhibitory effect on angiogenesis [46]. This evidence concerns the gene S100A9 and familial avascular necrosis of femoral head.